254571.fig.002
Figure 2: The duration of symptom for patients with wind-cold type common cold receiving 0.6 g SCC (group A), 1.2 g SCC (group B), or 1.2 g placebo (group C). (a) All symptom duration; (b) and (c) the duration of avertion to cold; (d) and (e) the nasal discharge.